Global X Genomics & Biotechnology UCITS ETF (ETR:GN0M)
7.99
-0.03 (-0.35%)
At close: Jun 18, 2026
58.45% (1Y)
| Assets | 26.39M |
| Expense Ratio | 0.60% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +58.45% |
| Volume | 15,318 |
| Open | 8.00 |
| Previous Close | 8.02 |
| Day's Range | 7.97 - 8.05 |
| 52-Week Low | 4.98 |
| 52-Week High | 8.04 |
| Beta | n/a |
| Holdings | 53 |
| Inception Date | Nov 2, 2021 |
About GN0M
GNOM.L was created on 2021-11-02 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 29.73m in AUM and 51 holdings. The Funds investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index
Asset Class Equity
Category Theme
Stock Exchange Deutsche Börse Xetra
Ticker Symbol GN0M
Provider Global X
Index Tracked Solactive Genomics v2 Index - Benchmark TR Net
Performance
GN0M had a total return of 58.45% in the past year, including dividends. Since the fund's inception, the average annual return has been -10.42%.
Top 10 Holdings
43.57% of assets| Name | Symbol | Weight |
|---|---|---|
| Guardant Health, Inc. | GH | 5.40% |
| Legend Biotech Corporation | LEGN | 4.84% |
| Twist Bioscience Corporation | TWST | 4.76% |
| Illumina, Inc. | ILMN | 4.56% |
| Moderna, Inc. | MRNA | 4.16% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 4.11% |
| Natera, Inc. | NTRA | 4.06% |
| Vertex Pharmaceuticals Incorporated | VRTX | 3.96% |
| Veracyte, Inc. | VCYT | 3.91% |
| BioMarin Pharmaceutical Inc. | BMRN | 3.81% |